These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30988246)

  • 41. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function.
    Horii M; Matsumoto T; Uemura S; Sugawara Y; Takitsume A; Ueda T; Nakagawa H; Nishida T; Soeda T; Okayama S; Somekawa S; Ishigami K; Takeda Y; Kawata H; Kawakami R; Saito Y
    J Cardiol; 2013 Jun; 61(6):410-6. PubMed ID: 23618914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes.
    Gregg LP; Adams-Huet B; Li X; Colbert G; Jain N; de Lemos JA; Hedayati SS
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28679558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
    Matsuo A; Iida A; Tanimoto M; Matsushita M; Miyamoto K
    Ren Fail; 2014 Sep; 36(8):1291-7. PubMed ID: 24975675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15.
    Patel SK; Velkoska E; Gayed D; Ramchand J; Lesmana J; Burrell LM
    BMC Nephrol; 2018 Jul; 19(1):159. PubMed ID: 29970016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
    Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
    Beraldo JI; Benetti A; Borges-Júnior FA; Arruda-Junior DF; Martins FL; Jensen L; Dariolli R; Shimizu MH; Seguro AC; Luchi WM; Girardi ACC
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease].
    Quiroga B; Goicoechea M; García de Vinuesa S; Verde E; Verdalles U; Yuste C; Reque J; Luño J
    Med Clin (Barc); 2012 Jun; 139(3):98-102. PubMed ID: 21807382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
    Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers.
    Terse PS; Joshi PS; Bordelon NR; Brys AM; Patton KM; Arndt TP; Sutula TP
    Int J Toxicol; 2016 May; 35(3):284-93. PubMed ID: 26838190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NT-proBNP in the Prognosis of Death or Need for Renal Replacement Therapy in Patients with Stage 3-5 Chronic Kidney Disease.
    Gromadziński L; Januszko-Giergielewicz B; Czarnacka K; Pruszczyk P
    Cardiorenal Med; 2019; 9(2):125-134. PubMed ID: 30726840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
    Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
    Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natriuretic Peptides as Cardiovascular Safety Biomarkers in Rats: Comparison With Blood Pressure, Heart Rate, and Heart Weight.
    Engle SK; Watson DE
    Toxicol Sci; 2016 Feb; 149(2):458-72. PubMed ID: 26609138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
    He T; Chen L; Chen Y; Han Y; Yang WQ; Jin MW
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):109-20. PubMed ID: 22183794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.
    Panizo S; Barrio-Vázquez S; Naves-Díaz M; Carrillo-López N; Rodríguez I; Fernández-Vázquez A; Valdivielso JM; Thadhani R; Cannata-Andía JB
    Nephrol Dial Transplant; 2013 Nov; 28(11):2735-44. PubMed ID: 24013683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sitagliptin and shock wave-supported peripheral blood derived endothelial progenitor cell therapy effectively preserves residual renal function in chronic kidney disease in rat-role of dipeptidyl peptidase 4 inhibition.
    Sung PH; Chen KH; Li YC; Chiang JY; Lee MS; Yip HK
    Biomed Pharmacother; 2019 Mar; 111():1088-1102. PubMed ID: 30841422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glibenclamide improves kidney and heart structure and function in the adenine-diet model of chronic kidney disease.
    Diwan V; Gobe G; Brown L
    Pharmacol Res; 2014 Jan; 79():104-10. PubMed ID: 24291534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between N-terminal pro-B-type natriuretic peptide plasma levels and renal function evaluated with different formulae in older adult subjects admitted because of dyspnea.
    Fabbian F; De Giorgi A; Portaluppi F; Zuliani G
    Gerontology; 2012; 58(1):50-5. PubMed ID: 21540563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.